Ulrika Andersson

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation

Ziad Hijazi, Jonas Oldgren, Ulrika Andersson et al. · Circulation · 2012 · 398 citations

Medicine, Cardiology, Clinical Cardiology +16

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation

Ziad Hijazi, Stefan H. Hohnloser, Jonas Oldgren et al. · Circulation · 2013 · 397 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation

Lars Wallentin, Ziad Hijazi, Ulrika Andersson et al. · Circulation · 2014 · 308 citations

Medicine, Cardiology, Pharmacology +16

The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

Roopinder K. Sandhu, Justin A. Ezekowitz, Ulrika Andersson et al. · European Heart Journal · 2016 · 235 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation

Ziad Hijazi, Lars Wallentin, Agneta Siegbahn et al. · Journal of the American College of Cardiology · 2013 · 230 citations

Medicine, Cardiology, Pharmacology +12